Daniel Meller Selected Research

GS 101

9/2014	Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
9/2009	GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Meller Research Topics

Disease

6	Limbal Stem Cell Deficiency 06/2019 - 02/2009
3	Melanoma (Melanoma, Malignant) 06/2019 - 04/2006
3	Neoplasms (Cancer) 06/2019 - 01/2010
3	Inflammation (Inflammations) 01/2017 - 04/2002
3	Ulcer 12/2013 - 04/2002
2	Atrophy 09/2022 - 05/2022
2	Hyperpigmentation 05/2022 - 01/2020
2	Macular Edema 02/2022 - 01/2014
2	Cicatrix (Scar) 07/2021 - 04/2011
2	Glaucoma 06/2019 - 01/2019
2	Burns 01/2017 - 01/2010
2	Corneal Neovascularization 09/2014 - 09/2009
2	Keratitis 09/2014 - 09/2007
2	Neoplasm Metastasis (Metastasis) 10/2010 - 04/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2010 - 02/2009
2	Pterygium 01/2010 - 02/2003
1	Keratoconus 06/2021
1	Macular Degeneration (Age-Related Maculopathy) 01/2020
1	Sjogren's Syndrome (Sjogren Syndrome) 06/2019
1	Geographic Atrophy 05/2018
1	Chemical Burns (Chemical Burn) 01/2017
1	Aphakia 01/2014
1	Corneal Diseases (Corneal Disease) 01/2012
1	Nevus (Nevi) 10/2010
1	Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa) 04/2010
1	Conjunctivitis 01/2010
1	Aniridia 01/2010
1	Eye Injuries (Eye Injury) 01/2010
1	Epidermolysis Bullosa 01/2010
1	Lymphoma (Lymphomas) 10/2004
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 10/2004
1	Corneal Ulcer 07/2004
1	Graves Ophthalmopathy 07/2004
1	Corneal Perforation 04/2002

Drug/Important Bio-Agent (IBA)

5	Retinaldehyde (Retinal)IBA 09/2022 - 01/2019
2	Protons (Proton)IBA 06/2019 - 04/2006
2	GS 101IBA 09/2014 - 09/2009
2	Insulin Receptor Substrate ProteinsIBA 09/2014 - 09/2009
2	Antisense OligonucleotidesIBA 09/2014 - 09/2009
2	Ophthalmic Solutions (Eye Drops)IBA 09/2014 - 09/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022
1	afliberceptIBA 02/2022
1	Macular PigmentIBA 05/2018
1	AcidsIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 09/2015
1	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2015
1	Capsules (Microcapsules)IBA 01/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2011
1	AntigensIBA 10/2010
1	Chondroitin Sulfate ProteoglycansIBA 10/2010
1	N 30IBA 01/2010
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2010
1	MucinsIBA 03/2009
1	CytokinesIBA 09/2007
1	Botulinum Toxins (Botulinum Toxin)IBA 07/2007
1	Type A Botulinum Toxins (Botox)FDA Link 07/2007
1	Rituximab (Mabthera)FDA Link 10/2004
1	Monoclonal AntibodiesIBA 10/2004
1	Proteins (Proteins, Gene)FDA Link 02/2003
1	Insulin-Like Growth Factor Binding ProteinsIBA 02/2003
1	Insulin-Like Growth Factor Binding Protein 2IBA 02/2003
1	Messenger RNA (mRNA)IBA 02/2003
1	Insulin-Like PeptidesIBA 02/2003
1	Complementary DNA (cDNA)IBA 02/2003
1	Nylons (Nylon)IBA 04/2002

Therapy/Procedure

12	Transplantation 01/2017 - 04/2002
6	Therapeutics 02/2022 - 04/2002
3	Corneal Transplantation (Keratoplasty) 07/2021 - 07/2007
3	Radiotherapy 06/2019 - 10/2004
1	Penetrating Keratoplasty 06/2021
1	Intraocular Lenses (Intraocular Lens) 01/2014
1	Autologous Transplantation 04/2010
1	Intraocular Lens Implantation 02/2009
1	Cataract Extraction 02/2009
1	Hematopoietic Stem Cell Transplantation 02/2009
1	Contraindications 10/2004
1	Decompression 07/2004
1	Inlays (Inlay) 07/2004
1	Sutures (Suture) 04/2002